Department of Radiotherapy Oncology, Hangzhou Cancer Hospital, Hangzhou, People's Republic of China.
Onco Targets Ther. 2015 Sep 9;8:2503-7. doi: 10.2147/OTT.S87222. eCollection 2015.
To investigate the impact of chemotherapy and/or radiotherapy on disease-free survival (DFS) and overall survival (OS) rates of patients with thymic carcinoma after complete resection.
Between 2001 and 2013, 54 patients with complete resection of thymic carcinoma in Hangzhou Cancer Hospital were retrospectively reviewed. The Kaplan-Meier method was used to evaluate the survival rates. The Cox proportional hazard model was used for multivariate analysis.
Among the 54 patients, Masaoka stage I was observed in seven patients, II in 22 patients, and III in 25 patients. Sixteen patients received adjuvant chemotherapy (six with chemotherapy alone and ten with radiotherapy and chemotherapy), 25 patients received adjuvant radiotherapy, and 13 patients did not receive radiotherapy and/or chemotherapy. The 5-year DFS and OS rates for all patients were 63.0% and 73.4%, respectively. Univariate analysis revealed that radiotherapy was significantly associated with DFS and OS (P=0.014 and P=0.029, respectively), while adjuvant chemotherapy was not (P=0.122 and P=0.373, respectively). Multivariate analysis showed that adjuvant radiotherapy increased DFS (P=0.041), but not OS (P=0.051).
Complete resection followed by adjuvant radiotherapy increased disease-free rates of thymic carcinoma patients.
探讨完全切除后化疗和/或放疗对胸腺癌患者无病生存率(DFS)和总生存率(OS)的影响。
回顾性分析 2001 年至 2013 年杭州肿瘤医院 54 例完全切除胸腺癌患者的临床资料。采用 Kaplan-Meier 法评估生存率,Cox 比例风险模型进行多因素分析。
54 例患者中,Masaoka Ⅰ期 7 例,Ⅱ期 22 例,Ⅲ期 25 例。16 例患者接受辅助化疗(单纯化疗 6 例,放化疗 10 例),25 例患者接受辅助放疗,13 例患者未接受放疗和/或化疗。所有患者的 5 年 DFS 和 OS 率分别为 63.0%和 73.4%。单因素分析显示,放疗与 DFS 和 OS 显著相关(P=0.014 和 P=0.029),而辅助化疗与 DFS 和 OS 无关(P=0.122 和 P=0.373)。多因素分析显示,辅助放疗可提高 DFS(P=0.041),但不能提高 OS(P=0.051)。
完全切除后辅助放疗可提高胸腺癌患者的无病生存率。